Skip to main content

Clinical Characteristics of Incident Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in TriNetX: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
    Description

    In this analysis, we aimed to describe clinical characteristics of patients with an incident medication fact record for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (overall and by drug) in the TriNetX Live™ platform. Seven GLP-1 RAs were examined, including albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide.

    The study period includes data from October 1, 2017 to September 30, 2023. We ran this query on August 7, 2024. This query contains data from 61 Health Care Organizations (HCOs) provided through the TriNetX Live™ platform in their USA Network Minimal Shift, which includes HCOs that may implement date shifting between 0 and 14 days in either direction. This includes all HCOs from the USA Network without date shifting.

    Additional Details
    FDA Center
    CDER
    Time Period
    October 1, 2017 – September 30, 2023
    Analysis Type
    TriNetX Analysis
    Population / Cohort
    All individuals
    Data Sources
    TriNetX Live™ USA Network